On December 18th, Hainan Free Trade Port Boao Lecheng International Medical Tourism Pilot Zone (hereinafter referred to as Lecheng Pilot Zone) added a new hospital - Boao Lecheng Aier Ophthalmology, and Aier Ophthalmology International Clinical Research Base was also officially established. In the future, the hospital will carry out high-end licensed medical services and real-world clinical research with the help of the concession policy of lecheng Pilot Zone, and strive to enhance the incubation and introduction of ophthalmic clinical technology innovation.
Boao Lecheng Aier Eye Hospital real view
With the awakening of national health awareness, the demand for high-level medical services and world-class innovative pharmaceutical devices continues to grow. Lecheng Pilot Zone, as the only medical special zone in China, has been licensed to introduce foreign listed but domestic unlisted pharmaceutical and medical technology resources by virtue of preferential policies such as first-come, first-served trials, and has become the gateway for world-class innovative pharmaceutical devices to enter China. This also means that the latest ophthalmic drugs and medical devices that have been approved by developed countries and alliances such as the United States, Japan, and the European Union but have not yet been listed in China can be used preferentially in Boao Lecheng Aier Eye Hospital.
Therefore, in this context, Boao Lecheng Aier Eye Hospital will introduce the first batch of international innovative refractive cataract crystals, new drugs for dry eye treatment, new drugs for fundus injection and fundus photographic equipment through the concession policy of Lecheng Park, so as to meet the needs of global eye disease patients.
Aier Ophthalmology will also cooperate with sub-specialist leaders, well-known experts, scientific research talents, Aier overseas doctor teams and global partners to conduct multi-site practice at Boao Lecheng Aier Eye Hospital, attract more ophthalmic talents at home and abroad with the help of the policy advantages of Hainan Free Trade Port, and build an ophthalmic diagnosis and treatment service system that is in line with international standards. It is reported that Aier Ophthalmology will continue to carry out clinical research in many sub-specialties such as refractive, optometry, cataracts, glaucoma, fundus disease, corneal disease, orbital disease and so on.
Fu Zhu, deputy director of the Lecheng Pioneer District Management Bureau, delivered a speech on the spot
Fu Zhu, deputy director of the Lecheng Pioneer District Administration, said that as of now, 17 medical institutions have opened in Lecheng and more than 11 are under construction. Using Lecheng's policy of first-come, first-served, 51 academician expert teams have been introduced to work together to create first-class ophthalmology, otolaryngology, cardiovascular, oncology and other important specialties. Nowadays, Aier Ophthalmology has entered Lecheng and fully combined its international advantages with Lecheng's policy advantages, which is conducive to gathering advanced forces in the field of ophthalmology and enhancing the professional advantages in the field of ophthalmology diagnosis and treatment in Lecheng.
Written by: Nandu reporter Zeng Wenqiong
Intern: Liao Yingqi